Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCORI Should Consider Health IT In Setting Research Priorities – Board’s Weisman

Executive Summary

As the Patient-Centered Outcomes Research Institute begins determining its national priorities and research agenda, one board of governors member, Johnson & Johnson executive Harlan Weisman, is stressing the importance of including health information technology in that process.

You may also be interested in...

EHRs Become A Stronger Research Tool Under Proposed Stage 2 Meaningful Use Rule

Use of electronic health records to report data to disease registries, for both cancer and non-cancer conditions, becomes an optional objective for providers to demonstrate “meaningful use” of EHRs under CMS’ proposed stage 2 requirements. An objective to identify patients for potential research opportunities also carries over to the stage 2 proposal.

EHR “Meaningful Use” Requirements Raise Expectations For Health Information Exchange In Stage 2

CMS highlights the greater role that health information exchange will play in stage 2 meaningful use for electronic health records and sets the stage for an even more robust use of health data to promote safety and efficiency as the agency moves toward stage 3.

PCORI Methodology Committee Begins Examining How Best To Interface With EHRs

Committee conducts interviews with 33 stakeholders, which reveal gaps and needs, as well as potential areas where Patient-Centered Outcomes Research Institute can help bridge research with electronic sources of data.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts